OncLive® and The Ruesch Center Announce the Honorees of The Luminary Awards in GI Cancers
Honorees are recognized for their tremendous devotion and leadership
in research, clinical care and advocacy in GI cancer.
OncLive®, the leading digital provider of resources and information to
oncology professionals, in conjunction with The Ruesch Center for the
Cure of Gastrointestinal Cancers, will honor five outstanding
individuals for their commitment to improving the lives of patients
affected by gastrointestinal cancer. The Luminary Awards in GI Cancers
reception will be held Thursday, November 29, at the Washington Hilton
in Washington, D.C.
“The Luminary Awards serves to acknowledge the lifetime contributions
made by truly special, dedicated, visionary individuals. Our current
successes in GI cancer would not be possible without the work of these
remarkable people. The Ruesch Center goal of curing all GI cancers is
inspired by their efforts and contributions,” said John Marshall, MD,
director of The Ruesch Center for the Cure of Gastrointestinal Cancers.
“We are honored to recognize these five remarkable individuals for their
continuous support of the gastrointestinal cancer community,” said
Michael J. Hennessy Jr., president of MJH Associates Inc., parent
company of OncLive®. “We look forward to dedicating a night to these
honorees who make a difference every day.”
The Luminary Awards in GI Cancers winners are:
-
Richard L. Schilsky, M.D., FACP, FASCO, FSCT;American
Society of Clinical Oncology (ASCO)
A highly respected leader in
the field of oncology, Schilsky is the senior vice president and chief
medical officer of ASCO, as well as a past president. Previously, he
served as the chief of hematology and oncology in the department of
medicine and deputy director of the University of Chicago Medicine
Comprehensive Cancer Center. He specializes in new drug development
and treatment of gastrointestinal cancers. His impressive experience
and proven track record in both clinical medicine and clinical
research reflect his deep passion for cancer medicine. Schilsky has
spent most of his career at the University of Chicago, where he joined
the faculty in 1984, rising to the rank of professor of medicine and
serving in many roles, including associate dean for clinical research
in the biological sciences division and director of the cancer center.
Earlier in his career, he worked in the clinical pharmacology branch
of the division of cancer treatment at the National Cancer Institute
and was an assistant professor in the department of internal medicine,
division of hematology and oncology, at the University of
Missouri-Columbia School of Medicine. He was also the head of the
hematology/medical oncology unit at Harry S. Truman Veterans’ Hospital
in Columbia. Schilsky is also past chair of the Cancer and Leukemia
Group B (CALGB) and a former member and chair of the Board of
Scientific Advisors of the National Cancer Institute and of the
Oncology Drugs Advisory Committee of the Food and Drug Administration.
-
Paul H. Sugarbaker, M.D., FACS, FRCS; Medstar Washington
Hospital Center
Sugarbaker is the chief of the peritoneal surface
malignancy program and the director of the Center for Gastrointestinal
Malignancies at Medstar Washington Hospital Center. In 1989, he become
the medical director of the Washington Cancer Institute at MedStar
Washington Hospital Center. Currently, his clinical and investigative
work is concentrated on the treatment of the peritoneal surface
dissemination of cancer, known as peritoneal carcinomatosis. He has
developed, perfected and popularized the combined treatments of cancer
surgery with warm chemotherapy, infused into the open abdomen toward
the end of surgical intervention. He has written over 900 articles and
book chapters, edited seven books, produced 24 videos and received
four honorary professorships.
-
Daniel D. Von Hoff, M.D., FACP;Translational Genomics
Research Institute, HonorHealth, US Oncology and Mayo Clinic
Von
Hoff is the physician-in-chief and distinguished professor at the
Translational Genomics Research Institute in Phoenix, chief scientific
officer at HonorHealth and US Oncology, and a professor of medicine at
Mayo Clinic. Von Hoff and colleagues’ discoveries have led to
tremendous improvements in survival for patients with pancreatic
cancer. Currently, he and his colleagues are concentrating on the
development of molecularly targeted therapies for patients with
pancreatic and other advanced cancers. Von Hoff has written more than
648 papers, 138 book chapters and over 1085 abstracts. He received the
2010 David A. Karnofsky Memorial Award from ASCO for his outstanding
contributions to cancer research leading to significant improvement in
patient care.
Robert Goldsmith, vice president of OncLive® states, “this awards
ceremony not only recognizes the five outstanding individuals, it also
honors all of the unacknowledged heroes in the GI cancers community.
Each of these winners helps propel the field of GI cancer through their
dedicated work and passion for improving the lives of those impacted by
gastrointestinal cancer.”
The Ruesch Center for the Cure of Gastrointestinal Cancers is part of
the Georgetown Lombardi Comprehensive Cancer Center and focuses on
personalized patient care and fighting against gastrointestinal cancers.
The Ruesch Center provides the highest standard of care and
individualized cures through clinical trials and research, education and
advocacy, and regional and global alliances.
For more information about the reception, please visit https://www.onclive.com/luminary-awards.
About OncLive®
A digital platform of resources for practicing oncologists, OncLive®
offers oncology professionals information they can use to help provide
the best patient care. OncLive.com is the official website for the MJH
Associates Inc. Oncology Specialty Group, which publishes OncologyLive®,
Oncology Nursing News® and more. MJH Associates Inc. is a
full-service health care communications company offering education,
research and medical media, including curetoday.com and CURE®
magazine, the largest U.S. consumer publication focused entirely on
cancer. Combining science and humanity to make cancer understandable, CURE®
reaches patients, cancer centers and advocacy groups.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005867/en/
OncLive® Media:
Alexandra Ventura, 609-716-7777, ext. 121
aventura@mjhassoc.com
More From BioPortfolio on "OncLive® and The Ruesch Center Announce the Honorees of The Luminary Awards in GI Cancers"